This study is designed to test the toxicity and potential benefit of immunotherapy in patients with recurrent, metastatic ovarian cancer for whom proven, effective therapeutic options are not available. Immunotherapy involves attempts to use the immune system or products of the immune system to fight cancer. Currently there is no FDA approved immunotherapy treatment for ovarian cancer One of the ways cancer patients have been treated in the past with immunotherapy is with an anti-tumor vaccine. This means that the patient's tumor is isolated and purified, then is treated with irradiation or the tumor is disrupted (so the tumor cells won't grow) and injected under the skin. The tumor cells are usually given with another agent called an adjuvant that is designed to stimulate the immune system resulting in recognition of the cancer cells by the immune system. It is hoped that this approach will then lead to destruction of other cancer cells elsewhere in the body by the cells of the immune system. This specific study is being conducted to determine the safety, side effects, and toxicity of an ovarian cancer cell vaccine that consists of tumor-pulsed dendritic cells. Another reason this study is being conducted is to determine if the vaccine causes an immune response in cancer patients. Patients on this study will also be monitored to determine if their tumor decreases in size following vaccination therapy. All patients who participate in this study will receive the tumor-pulsed dendritic cell vaccine. A few patients will receive a vaccine of their own cancer cells without the dendritic cells in addition to the vaccine of their own cancer cells pulsed onto dendritic cells. The purpose of treating this sub-group of patients is to compare the immunologic response in these patients to the two different vaccines. Different patients will receive different numbers of tumor-pulsed dendritic cells injected under their skin. Each individual patient will receive only one amount of tumor-pulsed dendritic cells.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000042-40
Application #
6408517
Study Section
General Clinical Research Centers Committee (CLR)
Project Start
1977-12-01
Project End
2001-02-28
Budget Start
Budget End
Support Year
40
Fiscal Year
2000
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Robarge, Jason D; Desta, Zereunesay; Nguyen, Anne T et al. (2017) Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. Breast Cancer Res Treat 161:453-461
Crane, Natania A; Jenkins, Lisanne M; Bhaumik, Runa et al. (2017) Multidimensional prediction of treatment response to antidepressants with cognitive control and functional MRI. Brain 140:472-486
Hertz, Daniel L; Speth, Kelly A; Kidwell, Kelley M et al. (2017) Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. Breast Cancer Res Treat 165:659-668
Hertz, D L; Kidwell, K M; Seewald, N J et al. (2017) Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer. Pharmacogenomics J 17:521-527
Kadakia, Kunal C; Kidwell, Kelley M; Seewald, Nicholas J et al. (2017) Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors. Breast Cancer Res Treat 164:411-419
Spengler, Erin K; Kleiner, David E; Fontana, Robert J (2017) Vemurafenib-induced granulomatous hepatitis. Hepatology 65:745-748
Heidemann, Lauren; Law, James; Fontana, Robert J (2017) A Text Searching Tool to Identify Patients with Idiosyncratic Drug-Induced Liver Injury. Dig Dis Sci 62:615-625
Law, Ian H; Alam, Osman; Bove, Edward L et al. (2016) Follow-Up of a Prospective Surgical Strategy to Prevent Intra-Atrial Reentrant Tachycardia After the Fontan Operation. Circ Arrhythm Electrophysiol 9:
Schrepf, Andrew; Harper, Daniel E; Harte, Steven E et al. (2016) Endogenous opioidergic dysregulation of pain in fibromyalgia: a PET and fMRI study. Pain 157:2217-2225
As-Sanie, Sawsan; Kim, Jieun; Schmidt-Wilcke, Tobias et al. (2016) Functional Connectivity is Associated With Altered Brain Chemistry in Women With Endometriosis-Associated Chronic Pelvic Pain. J Pain 17:1-13

Showing the most recent 10 out of 1380 publications